A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours

Summary

This is the first study to test SHR-1802 in humans. The primary purpose of this study is to see if SHR-1802 is safe and tolerable for patients with locally advanced/unresectable or metastatic malignancies that are refractory to available therapy or for which no standard therapy is available.

Timeline

Start

2020-06-17

Primary completion

2022-01-13

Completion

2022-03-15

Publications

• Deng T, Liu Z, Han Z, Zhou H, Liu R, Li Y, Li S, Xiu P, Wang S, Zhang Y, Ba Y. Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study. Ther Adv Med Oncol. 2023 Jul 29;15:17588359231186025. doi: 10.1177/17588359231186025. eCollection 2023.

Drugs

Indications